In February 1993, scientists reported a 50% reduction in MS attacks in 30 patients studied in a pilot trial of Myloral.

Myloral is an oral tolerance therapy designed to suppress the immune system in specific areas where autoimmune attacks such as multiple sclerosis occur.

